Literature DB >> 25223568

Treatment of pediculosis capitis: a critical appraisal of the current literature.

Hermann Feldmeier1.   

Abstract

Pediculosis capitis is the most common ectoparasitic disease in children in industrialized countries and extremely common in resource-poor communities of the developing world. The extensive use of pediculicides with a neurotoxic mode of action has led to the development and spread of resistant head lice populations all over the world. This triggered the development of compounds with other modes of action. The current literature on treatment approaches of head lice infestation was searched, and published randomized controlled trials were critically analyzed. The following compounds/family of compounds were identified: spinosad, a novel compound with a new neurotoxic mode of action, isopropyl myristate, 1,2-octanediol, ivermectin, plant-based products, and dimeticones. The efficacy and safety of these compounds are reviewed and recommendations for the treatment of pediculosis capitis in individuals as well as the interruption of ongoing epidemics are provided.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25223568     DOI: 10.1007/s40257-014-0094-4

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  10 in total

Review 1.  Paediatrics: how to manage pediculosis capitis.

Authors:  Alexander K C Leung; Joseph M Lam; Kin Fon Leong; Benjamin Barankin; Kam Lun Hon
Journal:  Drugs Context       Date:  2022-03-14

Review 2.  Human pediculosis, a global public health problem.

Authors:  Yi-Tian Fu; Chaoqun Yao; Yuan-Ping Deng; Hany M Elsheikha; Renfu Shao; Xing-Quan Zhu; Guo-Hua Liu
Journal:  Infect Dis Poverty       Date:  2022-05-26       Impact factor: 10.485

3.  Toxicity and potential utility of ivermectin and moxidectin as xenointoxicants against the common bed bug, Cimex lectularius L.

Authors:  Johnathan M Sheele; Gale E Ridge
Journal:  Parasitol Res       Date:  2016-04-18       Impact factor: 2.289

4.  Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community.

Authors:  Thérèse M Kearns; Richard Speare; Allen C Cheng; James McCarthy; Jonathan R Carapetis; Deborah C Holt; Bart J Currie; Wendy Page; Jennifer Shield; Roslyn Gundjirryirr; Leanne Bundhala; Eddie Mulholland; Mark Chatfield; Ross M Andrews
Journal:  PLoS Negl Trop Dis       Date:  2015-10-30

5.  Treatment of tungiasis with a two-component dimeticone: a comparison between moistening the whole foot and directly targeting the embedded sand fleas.

Authors:  Per Nordin; Marlene Thielecke; Nicholas Ngomi; George Mukone Mudanga; Ingela Krantz; Hermann Feldmeier
Journal:  Trop Med Health       Date:  2017-03-10

6.  The efficacy of Australian essential oils for the treatment of head lice infestation in children: A randomised controlled trial.

Authors:  Kerryn A Greive; Tanya M Barnes
Journal:  Australas J Dermatol       Date:  2017-03-07       Impact factor: 2.875

7.  Head louse egg and nit remover-a modern "Quest for the Holy Grail".

Authors:  Elizabeth R Brunton; Ian P Whelan; Rebecca French; Mark N Burgess; Ian F Burgess
Journal:  PeerJ       Date:  2019-04-15       Impact factor: 2.984

Review 8.  Where Are We With Human Lice? A Review of the Current State of Knowledge.

Authors:  Nadia Amanzougaghene; Florence Fenollar; Didier Raoult; Oleg Mediannikov
Journal:  Front Cell Infect Microbiol       Date:  2020-01-21       Impact factor: 5.293

9.  Effectiveness and tolerability of a squalane and dimethicone-based treatment for head lice.

Authors:  Leticia Martínez de Murguía Fernández; Gemma Puig Algora; Marta Bajona Roig; Gabriela Bacchini
Journal:  Parasitol Res       Date:  2021-04-02       Impact factor: 2.289

10.  Frequency of pyrethroid resistance in human head louse treatment: systematic review and meta-analysis.

Authors:  Jalal Mohammadi; Kourosh Azizi; Hamzeh Alipour; Mohsen Kalantari; Masoumeh Bagheri; Marzieh Shahriari-Namadi; Saeedeh Ebrahimi; Mohammad D Moemenbellah-Fard
Journal:  Parasite       Date:  2021-12-22       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.